PDCD1 and neoplasm: ,2 While anti-PD-1 mAb RMP1-14 did not show antitumor activity (Figures 6B–6D), Fc-optimized ipilimumab significantly reduced tumor growth, and its combination with PD-1 blockade further improved tumor control (Figures 6B–6D).